ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants

Study Summary

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.

Conditions

CML (Chronic Myelogenous Leukemia)Chronic Phase CML

Interventions / Drugs

ELVN-001

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment21 participants

Primary Completion—

Lead SponsorEnliven Therapeutics

Data Retrieved2026-04-11 04:12:48.346188+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.